Quanterix Corp (QTRX): restructuring charge — Quanterix terminates Akoya executives post-acquisition; expects $2.8M annual savings, $3.3M severance cost

Quanterix Corp

Terminating certain Akoya executives under its Executive Severance Plan as part of integration.
Expects annualized cash savings of ~$2.8M from reduced costs and streamlined operations.
Anticipates ~$3.3M in severance expenses, all cash expenditures, in 2025.
Terminations part of plan to realize synergies from recently closed Akoya acquisition.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Quanterix Corp announced a restructuring with charges of approximately $3.3 million affecting Akoya Biosciences, Inc. (newly acquired subsidiary) (certain executives of the Company's newly acquired subsidiary, Akoya Biosciences, Inc.).

Type: restructuring
Charge: approximately $3.3 million
Affected area: Akoya Biosciences, Inc. (newly acquired subsidiary)
Headcount: certain executives of the Company's newly acquired subsidiary, Akoya Biosciences, Inc.

Exact text from the filing

costs and streamlined operations and are expected to result in annualized cash savings of approximately $2.8 million. The Company expects to incur expenses of approximately $3.3 million, substantially all of which will be cash expenditures incurred in 2025 for severance required under Akoya’s Executive Severance Plan. The Company’s estimates are based on a

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Quanterix Corp filing history →

Source: SEC EDGAR

accession 0001503274-25-000074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.